A Phase 3 interventional study of Trilaciclib and Saline (0.9% NaCl) in Limited Stage Small Cell Lung Cancer, sponsored by Pharmacosmos A/S. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Supportive care
Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 112 open to participants now, 182 under way, 27 of them phase 3. Small Cell Lung Carcinoma · United States.
Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 166th largest by planned enrollment of the 550 interventional ones that give a count, is one of 37 that started in 2026, is one of 51 in phase 3, reaches primary completion later than 79 of the 181 other live ones, and was the 609th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 367 are open to participants now.
This study's planned enrollment of 120 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Browse Small Cell Lung Carcinoma studies →112 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now.
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 264 Small Cell Lung Carcinoma studies recruiting now, 173 (66%) set no upper age limit and 67 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →629 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 295 · Phase 2 302 · Phase 3 55 · Phase 4 3
First in 1991; this study’s year is marked. 37 started in 2026.
Median enrollment 55 across the 550 interventional studies, 111 across the 51 observational. Of the 417 that completed or were terminated, 173 (41%) have results posted.
294 of 629 have an industry lead sponsor. The 10 most frequent:
Pharmacosmos A/S is the lead sponsor of 36 studies on the registry; 5 are open to participants now.
Pharmacosmos A/S has 2 studies filed under Small Cell Lung Carcinoma — fewer than ten, so there is no comparison to draw.
44 of the studies in Small Cell Lung Carcinoma with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01064466Phase 3Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairPharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms | 2026-11-18 |
| NCT06646276Phase 3Bristol-Myers SquibbA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | 2027-08-17 |
| NCT07778316Phase 3AmgenPhase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) | 2027-09-24 |
| NCT04624204Phase 3Merck Sharp & Dohme LLCPlacebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | 2027-10-28 |
| NCT07473128Phase 3Pharmacosmos A/SEffect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer | 2027-10-31 |
Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, from their registry updates:
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:
Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer?
Participants will be randomised to receive either trilaciclib or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receives trilaciclib
Drug: Trilaciclib
Receives placebo
Drug: Saline (0.9% NaCl)
Intravenous infusion
Intravenous infusion
Also known as: dextrose
To Compare trilaciclib to placebo on prevention of myelosuppression
Duration and occurrence of severe neutropenia
Time frame: From enrollment and 4 months after
Number of all-cause chemotherapy dose reductions
Time frame: From enrollment and 4 months after
Occurrence of granulocyte colony-stimulating factor (G-CSF) administration
Time frame: From enrollment and 4 months after
Number of hospitalizations due to myelosuppression or sepsis
Time frame: From enrollment and 4 months after
Number of febrile neutropenia
Time frame: From enrollment and 4 months after
Occurrence of red blood cell (RBC) transfusions
Time frame: From enrollment and 4 months after
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Oct 2027, 13 months later.
Of 56 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 13 months is below that.
Counting every sponsor, half of 69 studies reached it within 44 months; a quarter within 31 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Jun 2026 → Sep 2026, primary completion Jun 2027 → Oct 2027 and completion Jun 2027 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trilaciclib